Stay updated with breaking news from Afm13. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.
The FDA has granted fast track designation to the first-in-class innate cell engager AFM13 plus AlloNK for the treatment of patients with relapsed/refractory Hodgkin lymphoma.
A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and... | June 9, 2023
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory peripheral T cell lymphoma is accepted as a poster presentationA trial in progress abstract of the... | May 11, 2023
The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.